FRI0523 Activating Transcription Factor 3 Regulates Canonical Tgf-[beta] Signaling in Systemic Sclerosis

Background Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by cellular stress including oxidative stress. Objectives The aim of this study was to analyze ATF3 in fi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2014-06, Vol.73, p.576
Hauptverfasser: Mallano, T, Palumbo-Zerr, K, Beyer, C, Dees, C, Huang, J, Tsonwin, H, Schett, G, Distler, J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 576
container_title Annals of the rheumatic diseases
container_volume 73
creator Mallano, T
Palumbo-Zerr, K
Beyer, C
Dees, C
Huang, J
Tsonwin, H
Schett, G
Distler, J
description Background Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by cellular stress including oxidative stress. Objectives The aim of this study was to analyze ATF3 in fibroblast activation and tissue fibrosis in systemic sclerosis (SSc). Methods Activation of ATF3 expression in skin tissue and in human dermal fibroblasts was determined by real-time PCR, Western blot and immunohistochemistry. ATF3 knockout fibroblasts were used to evaluate the effect of ATF3 on fibroblast activation and collagen release. Smad reporter assay were performed to study functional interactions between ATF3 and Smad signaling. The outcome of ATF3 knock-out mice and wildtype littermates was evaluated in the mouse models of bleomycin-induced dermal fibrosis and dermal fibrosis induced by overexpression of a constitutively active TGF-β receptor I (TBR). Results An increased expression of ATF3 was detected in the upper layer of the dermis of SSc patients on fibroblasts double stained for ATF3 and anti-prolyl-4-hydroxylase (p=0.0016). The overexpression of ATF3 persisted in cultured SSc fibroblasts. The upregulation of ATF3 was mediated by TGF-β. ATF3 expression was induced by TGF-β in cultured fibroblasts and in murine skin and treatment with the TBR inhibitor SD-208 prevented the induction of ATF3 in experimental fibrosis. ATF3 deficient fibroblasts were less sensitive to the pro-fibrotic effects of TGF-β with impaired induction of collagen mRNA and protein upon stimulation with TGF-β decreases of 64% (p=0.04) and 51% (p=0.03), respectively. Knockdown of ATF3 also protected from experimental fibrosis. In the model of bleomycin-induced fibrosis, dermal thickening was decreased by 70% (p=0.02), hydroxyproline content by 73% (p=0.035) and myofibroblast counts by 80% (p=0.0003) in AFT3 knockout mice compared to wildtype littermates. ATF3 knockout mice were also protected from TBR induced fibrosis. Function studies demonstrated that ATF3 is induced by Smad3 and regulates the pro-fibrotic effects of TGF-β. In addition reporter studies and analyses of the expression of classical Smad target genes such as PAI-1 demonstrated that binding of ATF3 to Smad3 stimulates the transcriptional activity of Smad3. Consistently, Smad3 reporter activity and the expression of PAI-1 upon stimulation with TGF-β were both strongly reduced in ATF3 knockout fibroblasts compared to c
doi_str_mv 10.1136/annrheumdis-2014-eular.3644
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1777971949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008690181</sourcerecordid><originalsourceid>FETCH-proquest_journals_17779719493</originalsourceid><addsrcrecordid>eNqNjM1KAzEUhYMoOP68Q6Dr1KSJmZmlFAfddmYnUq4xnd6SJjU3I_j2juADdHU4h-98jC2UXCql7QPEmPd-On4iiZVURvgpQF5qa8wFq5SxzTxbeckqKaUWprX1NbshOsxVNqqp2L7bvMrHleZPruA3FIwjHzJEchlPBVPkHbiSMtd848fZXjzxNcQU0UHgw7gTbx--wDvvcYwQ_v4Yef9DxR_R8d4FnxMh3bGrHQTy9_95yxbd87B-EaecviZPZXtIU54NtFV1Xbe1ak2rz6N-AQOkUos</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777971949</pqid></control><display><type>article</type><title>FRI0523 Activating Transcription Factor 3 Regulates Canonical Tgf-[beta] Signaling in Systemic Sclerosis</title><source>BMJ Journals - NESLi2</source><creator>Mallano, T ; Palumbo-Zerr, K ; Beyer, C ; Dees, C ; Huang, J ; Tsonwin, H ; Schett, G ; Distler, J</creator><creatorcontrib>Mallano, T ; Palumbo-Zerr, K ; Beyer, C ; Dees, C ; Huang, J ; Tsonwin, H ; Schett, G ; Distler, J</creatorcontrib><description>Background Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by cellular stress including oxidative stress. Objectives The aim of this study was to analyze ATF3 in fibroblast activation and tissue fibrosis in systemic sclerosis (SSc). Methods Activation of ATF3 expression in skin tissue and in human dermal fibroblasts was determined by real-time PCR, Western blot and immunohistochemistry. ATF3 knockout fibroblasts were used to evaluate the effect of ATF3 on fibroblast activation and collagen release. Smad reporter assay were performed to study functional interactions between ATF3 and Smad signaling. The outcome of ATF3 knock-out mice and wildtype littermates was evaluated in the mouse models of bleomycin-induced dermal fibrosis and dermal fibrosis induced by overexpression of a constitutively active TGF-β receptor I (TBR). Results An increased expression of ATF3 was detected in the upper layer of the dermis of SSc patients on fibroblasts double stained for ATF3 and anti-prolyl-4-hydroxylase (p=0.0016). The overexpression of ATF3 persisted in cultured SSc fibroblasts. The upregulation of ATF3 was mediated by TGF-β. ATF3 expression was induced by TGF-β in cultured fibroblasts and in murine skin and treatment with the TBR inhibitor SD-208 prevented the induction of ATF3 in experimental fibrosis. ATF3 deficient fibroblasts were less sensitive to the pro-fibrotic effects of TGF-β with impaired induction of collagen mRNA and protein upon stimulation with TGF-β decreases of 64% (p=0.04) and 51% (p=0.03), respectively. Knockdown of ATF3 also protected from experimental fibrosis. In the model of bleomycin-induced fibrosis, dermal thickening was decreased by 70% (p=0.02), hydroxyproline content by 73% (p=0.035) and myofibroblast counts by 80% (p=0.0003) in AFT3 knockout mice compared to wildtype littermates. ATF3 knockout mice were also protected from TBR induced fibrosis. Function studies demonstrated that ATF3 is induced by Smad3 and regulates the pro-fibrotic effects of TGF-β. In addition reporter studies and analyses of the expression of classical Smad target genes such as PAI-1 demonstrated that binding of ATF3 to Smad3 stimulates the transcriptional activity of Smad3. Consistently, Smad3 reporter activity and the expression of PAI-1 upon stimulation with TGF-β were both strongly reduced in ATF3 knockout fibroblasts compared to control cells (decreases of 56% (p=0.004) and 85% (p=0.02), respectively). Conclusions We demonstrate for the first time a key-role of ATF3 in fibroblast activation and tissue fibrosis in SSc. Inactivation of the ATF3 reduced the stimulatory effect of TGF-β on fibroblasts by interfering with canonical Smad signaling. Moreover, knockdown of ATF3 protected from experimental fibrosis in different mouse models. Considering the potent anti-fibrotic effects observed in this study, ATF3 might be a candidate for molecular targeted therapies of SSc. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3644</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2014-eular.3644</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2014-06, Vol.73, p.576</ispartof><rights>Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Mallano, T</creatorcontrib><creatorcontrib>Palumbo-Zerr, K</creatorcontrib><creatorcontrib>Beyer, C</creatorcontrib><creatorcontrib>Dees, C</creatorcontrib><creatorcontrib>Huang, J</creatorcontrib><creatorcontrib>Tsonwin, H</creatorcontrib><creatorcontrib>Schett, G</creatorcontrib><creatorcontrib>Distler, J</creatorcontrib><title>FRI0523 Activating Transcription Factor 3 Regulates Canonical Tgf-[beta] Signaling in Systemic Sclerosis</title><title>Annals of the rheumatic diseases</title><description>Background Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by cellular stress including oxidative stress. Objectives The aim of this study was to analyze ATF3 in fibroblast activation and tissue fibrosis in systemic sclerosis (SSc). Methods Activation of ATF3 expression in skin tissue and in human dermal fibroblasts was determined by real-time PCR, Western blot and immunohistochemistry. ATF3 knockout fibroblasts were used to evaluate the effect of ATF3 on fibroblast activation and collagen release. Smad reporter assay were performed to study functional interactions between ATF3 and Smad signaling. The outcome of ATF3 knock-out mice and wildtype littermates was evaluated in the mouse models of bleomycin-induced dermal fibrosis and dermal fibrosis induced by overexpression of a constitutively active TGF-β receptor I (TBR). Results An increased expression of ATF3 was detected in the upper layer of the dermis of SSc patients on fibroblasts double stained for ATF3 and anti-prolyl-4-hydroxylase (p=0.0016). The overexpression of ATF3 persisted in cultured SSc fibroblasts. The upregulation of ATF3 was mediated by TGF-β. ATF3 expression was induced by TGF-β in cultured fibroblasts and in murine skin and treatment with the TBR inhibitor SD-208 prevented the induction of ATF3 in experimental fibrosis. ATF3 deficient fibroblasts were less sensitive to the pro-fibrotic effects of TGF-β with impaired induction of collagen mRNA and protein upon stimulation with TGF-β decreases of 64% (p=0.04) and 51% (p=0.03), respectively. Knockdown of ATF3 also protected from experimental fibrosis. In the model of bleomycin-induced fibrosis, dermal thickening was decreased by 70% (p=0.02), hydroxyproline content by 73% (p=0.035) and myofibroblast counts by 80% (p=0.0003) in AFT3 knockout mice compared to wildtype littermates. ATF3 knockout mice were also protected from TBR induced fibrosis. Function studies demonstrated that ATF3 is induced by Smad3 and regulates the pro-fibrotic effects of TGF-β. In addition reporter studies and analyses of the expression of classical Smad target genes such as PAI-1 demonstrated that binding of ATF3 to Smad3 stimulates the transcriptional activity of Smad3. Consistently, Smad3 reporter activity and the expression of PAI-1 upon stimulation with TGF-β were both strongly reduced in ATF3 knockout fibroblasts compared to control cells (decreases of 56% (p=0.004) and 85% (p=0.02), respectively). Conclusions We demonstrate for the first time a key-role of ATF3 in fibroblast activation and tissue fibrosis in SSc. Inactivation of the ATF3 reduced the stimulatory effect of TGF-β on fibroblasts by interfering with canonical Smad signaling. Moreover, knockdown of ATF3 protected from experimental fibrosis in different mouse models. Considering the potent anti-fibrotic effects observed in this study, ATF3 might be a candidate for molecular targeted therapies of SSc. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3644</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNjM1KAzEUhYMoOP68Q6Dr1KSJmZmlFAfddmYnUq4xnd6SJjU3I_j2juADdHU4h-98jC2UXCql7QPEmPd-On4iiZVURvgpQF5qa8wFq5SxzTxbeckqKaUWprX1NbshOsxVNqqp2L7bvMrHleZPruA3FIwjHzJEchlPBVPkHbiSMtd848fZXjzxNcQU0UHgw7gTbx--wDvvcYwQ_v4Yef9DxR_R8d4FnxMh3bGrHQTy9_95yxbd87B-EaecviZPZXtIU54NtFV1Xbe1ak2rz6N-AQOkUos</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Mallano, T</creator><creator>Palumbo-Zerr, K</creator><creator>Beyer, C</creator><creator>Dees, C</creator><creator>Huang, J</creator><creator>Tsonwin, H</creator><creator>Schett, G</creator><creator>Distler, J</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20140601</creationdate><title>FRI0523 Activating Transcription Factor 3 Regulates Canonical Tgf-[beta] Signaling in Systemic Sclerosis</title><author>Mallano, T ; Palumbo-Zerr, K ; Beyer, C ; Dees, C ; Huang, J ; Tsonwin, H ; Schett, G ; Distler, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17779719493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mallano, T</creatorcontrib><creatorcontrib>Palumbo-Zerr, K</creatorcontrib><creatorcontrib>Beyer, C</creatorcontrib><creatorcontrib>Dees, C</creatorcontrib><creatorcontrib>Huang, J</creatorcontrib><creatorcontrib>Tsonwin, H</creatorcontrib><creatorcontrib>Schett, G</creatorcontrib><creatorcontrib>Distler, J</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mallano, T</au><au>Palumbo-Zerr, K</au><au>Beyer, C</au><au>Dees, C</au><au>Huang, J</au><au>Tsonwin, H</au><au>Schett, G</au><au>Distler, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FRI0523 Activating Transcription Factor 3 Regulates Canonical Tgf-[beta] Signaling in Systemic Sclerosis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2014-06-01</date><risdate>2014</risdate><volume>73</volume><spage>576</spage><pages>576-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by cellular stress including oxidative stress. Objectives The aim of this study was to analyze ATF3 in fibroblast activation and tissue fibrosis in systemic sclerosis (SSc). Methods Activation of ATF3 expression in skin tissue and in human dermal fibroblasts was determined by real-time PCR, Western blot and immunohistochemistry. ATF3 knockout fibroblasts were used to evaluate the effect of ATF3 on fibroblast activation and collagen release. Smad reporter assay were performed to study functional interactions between ATF3 and Smad signaling. The outcome of ATF3 knock-out mice and wildtype littermates was evaluated in the mouse models of bleomycin-induced dermal fibrosis and dermal fibrosis induced by overexpression of a constitutively active TGF-β receptor I (TBR). Results An increased expression of ATF3 was detected in the upper layer of the dermis of SSc patients on fibroblasts double stained for ATF3 and anti-prolyl-4-hydroxylase (p=0.0016). The overexpression of ATF3 persisted in cultured SSc fibroblasts. The upregulation of ATF3 was mediated by TGF-β. ATF3 expression was induced by TGF-β in cultured fibroblasts and in murine skin and treatment with the TBR inhibitor SD-208 prevented the induction of ATF3 in experimental fibrosis. ATF3 deficient fibroblasts were less sensitive to the pro-fibrotic effects of TGF-β with impaired induction of collagen mRNA and protein upon stimulation with TGF-β decreases of 64% (p=0.04) and 51% (p=0.03), respectively. Knockdown of ATF3 also protected from experimental fibrosis. In the model of bleomycin-induced fibrosis, dermal thickening was decreased by 70% (p=0.02), hydroxyproline content by 73% (p=0.035) and myofibroblast counts by 80% (p=0.0003) in AFT3 knockout mice compared to wildtype littermates. ATF3 knockout mice were also protected from TBR induced fibrosis. Function studies demonstrated that ATF3 is induced by Smad3 and regulates the pro-fibrotic effects of TGF-β. In addition reporter studies and analyses of the expression of classical Smad target genes such as PAI-1 demonstrated that binding of ATF3 to Smad3 stimulates the transcriptional activity of Smad3. Consistently, Smad3 reporter activity and the expression of PAI-1 upon stimulation with TGF-β were both strongly reduced in ATF3 knockout fibroblasts compared to control cells (decreases of 56% (p=0.004) and 85% (p=0.02), respectively). Conclusions We demonstrate for the first time a key-role of ATF3 in fibroblast activation and tissue fibrosis in SSc. Inactivation of the ATF3 reduced the stimulatory effect of TGF-β on fibroblasts by interfering with canonical Smad signaling. Moreover, knockdown of ATF3 protected from experimental fibrosis in different mouse models. Considering the potent anti-fibrotic effects observed in this study, ATF3 might be a candidate for molecular targeted therapies of SSc. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3644</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2014-eular.3644</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2014-06, Vol.73, p.576
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777971949
source BMJ Journals - NESLi2
title FRI0523 Activating Transcription Factor 3 Regulates Canonical Tgf-[beta] Signaling in Systemic Sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A58%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FRI0523%20Activating%20Transcription%20Factor%203%20Regulates%20Canonical%20Tgf-%5Bbeta%5D%20Signaling%20in%20Systemic%20Sclerosis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Mallano,%20T&rft.date=2014-06-01&rft.volume=73&rft.spage=576&rft.pages=576-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2014-eular.3644&rft_dat=%3Cproquest%3E4008690181%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777971949&rft_id=info:pmid/&rfr_iscdi=true